The genomic sequencing field has witnessed rapid evolution in recent years, marked by continuous innovation and breakthroughs. At a panel discussion during The Festival of Genomics and Biodata in Boston, key industry experts shed light on the latest advances in sequencing technology. Niall Lennon and Claire Hartmann emphasized the significant implications of decreasing costs and the emergence of multi-modal platforms in genomics research.
Niall Lennon highlighted the recent surge in technological advancements, with the introduction of new benchtop sequencers by Ultima and Roche. These developments offer a vast opportunity for the genomics community to capitalize on novel technologies. Claire Hartmann emphasized that ongoing innovations and competitive forces are effectively driving down costs, enabling larger-scale sequencing projects due to enhanced affordability.
In the realm of genomic sequencing, the paramount consideration varies based on the specific research objectives. While speed, accuracy, and workflow efficiency are crucial aspects, their relative importance depends on the nature of the research. For RNA-Seq, cost-effectiveness and high yield may outweigh the necessity for absolute accuracy. Conversely, applications such as detecting low-frequency mutations prioritize accuracy to discern signals from background noise.
The continuous drive to reduce sequencing costs raises questions about the sustainability of sequencing cores as businesses. While cost reduction benefits researchers by enabling more experiments and breakthroughs, sequencing facilities face challenges in balancing operational costs against diminishing revenues per sample. Factors such as labor costs, facility expenses, logistics, and reimbursement mechanisms play significant roles in the economic viability of sequencing cores.
As sequencing costs decline, researchers are empowered to execute more experiments within constrained budgets. While sequencing costs diminish in importance, upfront expenses such as sample preparation remain significant. Furthermore, the cost of data storage often goes unnoticed, leading institutions to impose limits on data retention due to the associated high costs.
Long-read sequencing platforms, exemplified by PacBio and Oxford Nanopore technologies, play pivotal roles in genomic research. These platforms offer distinct advantages in genome assembly and sequencing of degraded samples. PacBio’s long reads facilitate comprehensive genome analysis, particularly in rare disease diagnostics. Oxford Nanopore excels in sequencing degraded samples and detecting RNA modifications, expanding the capabilities of genomic research.
In the era of multi-omics, researchers strive to extract maximum information from individual samples. The integration of multi-modal approaches in sequencing technologies enables comprehensive analysis of various molecular entities. Companies are increasingly developing assays that support multi-omics research, reflecting a paradigm shift towards holistic data acquisition from diverse biological substrates.
Addressing challenges related to sequencing low-quality samples, advancements in technology have enabled sequencing from smaller sample amounts. PacBio’s SPRQ chemistry and amplification library prep kits have enhanced the sequencing of degraded samples, albeit with potential trade-offs in read length and yield. Establishing standardized protocols for tissue collection, storage, and preservation is crucial for optimizing genomic sequencing outcomes, particularly in scenarios involving degraded samples.
In a groundbreaking discovery, scientists at Vanderbilt University Medical Center have reported significant progress in DNA sequencing-based detection of residual disease, showcasing the potential of genomic sequencing in predicting treatment outcomes. This underscores the transformative impact of genomic sequencing in precision medicine and disease management.
Read more on frontlinegenomics.com